IMCLONE SYSTEMS IMCL (NASDAQ)

(NEW YORK)Shares of OSI Pharmaceuticals Inc. rose Friday after a Thomas Weisel Partners analysts initiated coverage of the biopharmaceutical company with an "Overweight" rating, citing accel...READ MORE

(NEW YORK)Large-cap biotech stocks are better positioned to bring investors returns during the second half of 2008 due to revenue gains and development deals, J.P. Morgan analysts said Tuesd...READ MORE

(WARSAW, Poland)Martha Stewart has been banned from Britain--but she got a warm welcome Friday in Poland, her grandparents' homeland. The lifestyle guru was planning to visit Britain in the co...READ MORE

(NEW YORK)The number of biotechnology-based blockbuster drugs on the market skyrocketed in 2007, as more drug companies focused research and marketing attention on the cell-based technology....READ MORE

(NEW YORK)ImClone Systems Inc.'s cancer drug Erbitux will likely see sales rise in 2009 with the approval of several new indications, according to Goldman Sachs, but Genentech Inc.'s...READ MORE

(NEW YORK)Wider international expansion, the confluence of pharmacies and drug suppliers, and a more aggressive generic drug industry will be in focus at the Goldman Sachs annual health care...READ MORE

(NEW YORK)Carl Icahn further escalated his proxy fight with Biogen Idec Inc., calling the biotechnology company's account of a failed sales process last year false.READ MORE